Clincosm LogoSign in Get a demo

immunotherapy

Showing 26 - 50 of 158
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Cancer, Radiation Therapy, Immunotherapy Trial in Taizhou (Toripalimab, Tegafur, IMRT)

Recruiting
  • Esophageal Cancer
  • +3 more
  • Taizhou, Zhejiang, China
  • +1 more
Apr 15, 2023

Immunotherapy, Immune Checkpoint Inhibitors, Immune-related Adverse Event Trial in Amiens (blood retriewal)

Recruiting
  • Immunotherapy
  • +5 more
  • blood retriewal
  • Amiens, Picardie, France
    CHU Amiens Picardie
Apr 3, 2023

NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage II
  • +3 more
  • Serplulimab combined with bevacizumab and first-line chemotherapy
  • Guangzhou, Guangdong, China
    Likun Chen
Apr 10, 2023

NSCLC, Stage II-IIIA, Immunotherapy Trial in Shanghai (Serplulimab and Chemotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • +3 more
  • Serplulimab and Chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 27, 2023

Patient Care Needs and Decision-Making Experience of Cancer and

Active, not recruiting
  • Supportive Care Needs
  • Immunotherapy
    • Taipei, Taiwan
      National Taiwan University
    Feb 20, 2023

    Checkpoint Inhibitors in Solid Tumors:Retrospective Real-world

    Recruiting
    • Immunotherapy
      • Nanjing, Jiangsu, China
        The First Affiliated Hospital with Nanjing Medical University
      Feb 8, 2023

      Immunotherapy, ADR Trial in Beijing

      Not yet recruiting
      • Immunotherapy
      • ADR
        • Beijing, Beijing, China
          Xuanwu Hospital
        Jan 27, 2023

        Immunotherapy Trial in Heidelberg (Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab)

        Not yet recruiting
        • Immunotherapy
        • Fecal microbiota transfer
        • +4 more
        • Heidelberg, Baden-Württemberg, Germany
        • +1 more
        Jan 19, 2023

        Leukemia, Lymphoma, Cardiotoxicity Trial in Philadelphia

        Completed
        • Leukemia
        • +4 more
          • Philadelphia, Pennsylvania
            Abramson Cancer Center of the University of Pennsylvania
          Jan 19, 2023

          Immunotherapy, Gastrict Cancer Trial in Fuzhou (Tislelizumab, Apatinib Mesylate, oxaliplatin)

          Recruiting
          • Immunotherapy
          • Gastrict Cancer
          • Fuzhou, China
            Fujian cancer hospital
          Jan 17, 2023

          Self Care, Symptom Management, Immunotherapy Trial in Ankara (TRAINING BOOKLET)

          Recruiting
          • Self Care
          • +3 more
          • TRAINING BOOKLET
          • Ankara, Turkey
            Ankara Medipol University
          Jan 4, 2023

          NSCLC, Immunotherapy Trial in Ann Arbor (Dexamthasone)

          Terminated
          • Non-Small Cell Lung Cancer
          • Immunotherapy
          • Ann Arbor, Michigan
            VA Ann Arbor Healthcare System, Ann Arbor, MI
          Jan 6, 2023

          Cognitive Remediation, Neuropsychology, Quality of Life Trial in Brussel (Integrative neurocognitive remediation therapy)

          Recruiting
          • Cognitive Remediation
          • +8 more
          • Integrative neurocognitive remediation therapy
          • Brussel, Brussels Hoofdstedelijk Gewest, Belgium
          • +1 more
          Dec 27, 2022

          Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor Trial in Beijing (TIL therapy)

          Recruiting
          • Tumor Infiltrating Lymphocytes
          • +5 more
          • TIL therapy
          • Beijing, Beijing, China
            Chinese PLA General Hospital
          Dec 19, 2022

          Immunotherapy Trial in Kars (Pre-post test)

          Recruiting
          • Immunotherapy
          • Pre-post test
          • Kars, Turkey
            Gönül GÖKÇAY
          Dec 10, 2022

          Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

          Recruiting
          • Immunotherapy
          • Multiple Myeloma
          • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
          • Zhengzhou, Henan, China
            Henan Cancer Hospital
          Dec 14, 2022

          Pathological Tumor and Lymph Node Responses After Neoadjuvant

          Completed
          • Non Small Cell Lung Cancer
          • +3 more
          • Timing of drug administration
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Nov 24, 2022

          Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy Trial in Guangzhou (drug, radiation, procedure)

          Recruiting
          • Esophageal Squamous Cell Carcinoma
          • +2 more
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Nov 24, 2022

          NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA Trial in France (Molecular monitoring by quantification of cell-free DNA)

          Recruiting
          • NSCLC
          • +2 more
          • Molecular monitoring by quantification of cell-free DNA
          • Besançon, France
          • +7 more
          Nov 18, 2022

          Monitoring Allergen Immunotherapy in Allergic Rhinitis

          Recruiting
          • Immunotherapy
          • +2 more
          • A nasal fluid Basophil Activation Test (BAT)
          • Arnhem, Netherlands
            Rijnstate Hospital
          Nov 10, 2022

          Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)

          Not yet recruiting
          • Esophageal Squamous Cell Carcinomas
          • +3 more
          • chemotherapy combined with PD-1 inhibitors
          • (no location specified)
          Nov 17, 2022

          Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

          Recruiting
          • Hepatocellular Carcinoma
          • +2 more
          • Nanjing, Jiangsu, China
            Jiangsu Province Hospital
          Nov 6, 2022

          HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

          Recruiting
          • HER2-negative Breast Cancer
          • +5 more
          • Camrelizumab with vinorelbine and cisplatin
          • Beijing, Beijing, China
            Peking University First Hospital
          Oct 15, 2022

          Advanced Gastric Carcinoma, Immunotherapy Trial in Beijing (Circulating exosomal lncRNA-GC1 detection)

          Completed
          • Advanced Gastric Carcinoma
          • Immunotherapy
          • Circulating exosomal lncRNA-GC1 detection
          • Beijing, Beijing, China
            Chinese PLA General Hospital
          Oct 7, 2022

          Allergy to Shrimp, Immunotherapy Trial in Bangkoknoi (shrimp allergy with intend to eat shrimp)

          Recruiting
          • Allergy to Shrimp
          • Immunotherapy
          • shrimp allergy with intend to eat shrimp
          • Bangkoknoi, Bangkok, Thailand
            Siriraj Hospital
          Sep 11, 2022